Clinical trial
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT00091117 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00091117 |
|---|---|
| Title | Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction |
| Official title | A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEPSponsored Organ Dysfunction Working Group |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hepatic Complications, Malignant Neoplasm |
| Intervention type | Drug, Other |
| Interventions | bortezomib, pharmacological study |
| Enrollment | 80 |
| Start date | Jul 1, 2004 |
| Primary completion | Mar 1, 2013 |
| First posted | Sep 8, 2004 |
| Last update posted | Dec 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: